Records 1 - 28 (of 28 Records) |
Query Trace: bioRxiv[original query] |
---|
Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2
Shi, Jianzhong et al.bioRxiv 10.1101/2020.03.30.015347
Key findings:
|
CONTAIN: An open-source shipping container laboratory optimised for automated COVID-19 diagnostics
Walker, Kenneth T. et al.bioRxiv 10.1101/2020.05.20.106625
Summary:
Presents an approach to expand testing capacity by converting a shipping container into a BSL-2+ laboratory to automate RT-PCR testing.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19
Cervia, Carlo et al.bioRxiv 10.1101/2020.05.21.108308
Key findings:
|
Single-cell analysis reveals the function of lung progenitor cells in COVID-19 patients
Zhao, Zixian et al.bioRxiv 10.1101/2020.07.13.200188
Summary:
In severe and critical cases of COVID-19, expansion of two classes of lung progenitor cells could influence alveolar cell regeneration and reestablishment of the epithelial barrier.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
SARS-CoV-2 lineage B.6 is the major contributor to transmission in Malaysia
Chong, Yoong Min et al.bioRxiv 10.1101/2020.08.27.269738
Key findings:
|
Susceptibility of midge and mosquito vectors to SARS-CoV-2 by natural route of infection
Balaraman, Velmurugan et al.bioRxiv 10.1101/2020.09.29.317289
Summary:
Studied the susceptibility of biting insects to SARS-CoV-2 after ingesting infected blood meal and concluded that biting insects do not pose a transmission risk to humans or animals.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
Zuo, J. et al.bioRxiv 10.1101/2020.11.01.362319
Key findings:
|
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Greaney, Allison J. et al.bioRxiv 10.1101/2020.12.31.425021
Key findings:
|
Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Columbus Ohio
Tu, Huolin et al.bioRxiv 10.1101/2021.01.12.426407
Summary:
Three SARS-CoV-2 clade 20C/G variants emerged in Ohio in December 2020; one has the N105Y mutation, similar to the B.1.1 lineage, and is likely highly transmissible.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United States
Pater, Adrian A. et al.bioRxiv 10.1101/2021.01.11.426287
Summary:
A new variant of SARS-CoV-2 within the B.1.2 lineage called 20C-US/clade G emerged in the southern US in May 2020 and is likely the dominant variant in the US; it has high transmissibility without causing increased disease severity.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers
Marot, Stphane et al.bioRxiv 10.1101/2021.03.05.434089
Key findings:
|
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Sandberg, John Tyler et al.bioRxiv 10.1101/2021.03.17.435581
Summary:
In both moderate and severe COVID-19 patients, neutralizing antibody titer, memory B cell response, and polyfunctional T cell responses were present 5 and 9 months after symptom onset, potentially providing long-term protection against reinfection.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil
Resende, Paola Cristina et al.bioRxiv 10.1101/2021.03.12.434969
Key findings:
|
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
Pegu, Amarendra et al.bioRxiv 10.1101/2021.05.13.444010
Key findings:
|
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies
Tada, Takuya et al.bioRxiv 10.1101/2021.05.14.444076
Summary:
Sera from mRNA-vaccinated individuals less efficiently neutralized SARS-CoV-2 B.1.617 and B.1.618 compared with wild-type SARS-CoV-2, D614G, or B.1.1.7; neutralizing titers to B.1.617 and B.1.618 were closer to those seen with variant B.1.351.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant
Moore, Penny L. et al.bioRxiv 10.1101/2021.06.09.447722
Key findings:
|
Mechanistic theory predicts the effects of temperature and humidity on inactivation of SARS-CoV-2 and other enveloped viruses
Morris, Dylan H. et al.bioRxiv 10.1101/2020.10.16.341883
Summary:
Study looking at the half-life of SARS-CoV-2, showing longer survival in cold temperatures and shorter survival at higher humidity (Figure).
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape
West, Anthony P. et al.bioRxiv 10.1101/2021.02.14.431043
Key findings:
|
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
Jongeneelen, Mandy et al.bioRxiv 10.1101/2021.07.01.450707
Summary:
Compared to B.1, a single dose of Ad26.COV1.2 (Johnson & Johnson/Janssen) vaccine had reduced neutralization sensitivity to SARS-Cov-2 variants B.1.351 (3.6-fold less), P.1 (3.4-fold less), and B.1.617.2 (1.6-fold less).
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
Choi, Angela et al.bioRxiv 10.1101/2021.06.28.449914
Summary:
One week after 2nd dose of mRNA-1273 (Moderna), sera from 8 individuals showed reduced neutralization (range 1.2- to 8.4-fold) for SARS-CoV-2 variants of concern compared to wild-type.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
Tada, Takuya et al.bioRxiv 10.1101/2021.07.02.450959
Summary:
SARS-CoV-2 Lambda had a 3-fold reduction in neutralization compared to wild-type by sera from convalescents (n = 8) and BNT162b2 (Pfizer/BioNTech, n = 15) or mRNA-1273 (Moderna, n = 6) vaccinees. While Lambda was about 3.6-fold resistant to neutralization by REGN10987, it was neutralized well by REGN10933.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Guebre-Xabier, Mimi et al.bioRxiv 10.1101/2020.08.18.256578
Key findings:
|
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Muik, Alexander et al.bioRxiv 10.1101/2021.01.18.426984
Summary:
The B.1.1.7 lineage of SARS-CoV-2 that was detected in the United Kingdom in September 2020, is unlikely to escape protection by the BioNTech-Pfizer mRNA vaccine.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
Vanshylla, Kanika et al.bioRxiv 10.1101/2021.01.26.428207
Key findings:
|
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Tada, Takuya et al.bioRxiv 10.1101/2021.07.19.452771
Key findings:
|
Antibody Evolution after SARS-CoV-2 mRNA Vaccination
Cho, Alice et al.bioRxiv 10.1101/2021.07.29.454333
Summary:
In the 5 months between 1st and 2nd doses of either mRNA vaccine, memory B-cells in SARS-CoV-2-nave recipients increased neutralizing activity, but only to those SARS-CoV-2 strains that dominated the initial response. In contrast, B-cells produced in convalescents had greater potential breadth and potency against mutant pseudoviruses. This suggests that boosting nave vaccinees with currently formulated mRNA vaccines might provide less protection against variants than vaccinating convalescents.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
Yadav, Pragya D. et al.bioRxiv 10.1101/2021.07.30.454511
Key findings:
|
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, Harold et al.bioRxiv 10.1101/2021.10.08.463699
Summary:
In serum from 136 COVID-19 patients (98 from Italy, 38 from Sweden), IgG antibodies were found 615 months after natural infection in 68% (anti-RBD [n = 30/44]) and 73% (anti-S [n = 32/44]) of patients. Lower antibody levels were associated with milder disease. Neutralizing antibodies were lower against variants of concern than against wild type. SARS-CoV-2 memory B and T cells were present in >95% of patients 615 months after infection.
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 18, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure